ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/paediatric/paediatric-cancer
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Paediatric cancer
43
trial(s) found.
NCT06465368
Curative
Phase 2
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING (
C4391025
)
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT06208657
Advanced
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in
Childhood and Adolescent Cancer (
OPTIMISE
>)
Irinotecan
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT06137118
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in
Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
>)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05828069
Haem
Phase 2
Recruiting
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis (
NCI-2022-06282
)
RAF inhibitor,type 2
Langerhans Cell Histiocytosis
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05735080
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer (
INX-315-01
)
CDK2 inhibitor
Breast cancer
Cancer
Carcinoma
Ovarian cancer
Solid tumour
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05640999
Curative
Phase 2
Recruiting
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER) (
EN10
)
Radiotherapy
cancer therapy
Endometrial cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05618028
Haem
Phase 1
Recruiting
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (
M23-324
)
MALT1 inhibitor
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
NCT05577416
Advanced
Phase 1
Recruiting
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (
AB-218-IIT-201
)
IDH1 R132 inhibitor
Low-grade glioma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05504291
Advanced
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
Retinoblastoma
WA
6009 - Perth - Perth Children's Hospital
NCT05503797
Advanced
Phase 2
Recruiting
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations (
F8394-201
)
RAF dimer inhibitor
Cancer
Central nervous system cancer
Melanoma
NOT Colorectal adenocarcinoma
NOT Melanoma
NOT Non-small cell lung cancer
NOT Pancreatic adenocarcinoma
NOT Thyroid cancer
Solid tumour
Thyroid cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05327894
Haem
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year with KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05304585
Advanced
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05286801
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (
NCI-2022-01992
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05094336
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced
MTAP
-null Solid Tumors
PRMT5 inhibitor
taxane
Gastric cancer
Gastroesophageal cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05005299
Haem
Phase 1
Recruiting
The
VICTORY
Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
BCL2 inhibitor
Leukaemia
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04870944
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Lymphoma
Osteosarcoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04759586
Haem
Phase 3
Recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (
NCI-2021-01071
)
anti-PD-1 monoclonal antibody
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04221035
Advanced
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
Acute lymphoblastic leukaemia
Leukaemia
Lymphoma
Mixed phenotype acute leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03590171
Haem
Phase 2
Recruiting
International Study for Treatment of High Risk
Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
>)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
NCT03394365
Haem
Phase 3
Recruiting
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (
ALLELE
)
allogeneic T-cell immunotherapy,EBV-targeting
anti-CD20 monoclonal antibody
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000082505
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T1- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre- emptive Therapy in AML): A Multi-arm, Precision- based, Recursive, Platform Trial - Gilteritinib+ Venetoclax (
AMLM26-T1--INTERCEPT
)
AXL/FLT3 inhibitor
BCL2 inhibitor
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000006549
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (
AMLM26-T3-INTERCEPT
)
BCL2 inhibitor
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622001232729
Haem
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Treosulfan
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
BCL2 inhibitor
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12621001444875
Advanced
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000273886
Curative
Phase 2
Recruiting
The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer -
ADELE
: a randomised phase 2 trial
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12619001031156
Haem
Phase 3
Recruiting
AMLM23- placebo-controlled study to compare the event free survival of patients receiving ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. (
HOVON150-AMLSG29-18
)
IDH1 R132 inhibitor
IDH2 inhibitor
placebo
Acute myeloid leukaemia
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12619000556145
Haem
Phase 1
Recruiting
A Phase I study to assess the safety of micro-dose lenalidomide as maintenance therapy post-allogeneic haematopoietic cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndromes, at high risk of relapse (
MicroLEN
)
immunomodulatory imide drug
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
Cyclophosphamide
Fludarabine
Radiotherapy
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
NCT06514794
Haem
Phase 2
Active not recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05848011
Advanced
Phase 2
Active not recruiting
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (
CP-MGD019-02
)
bispecific PD-1×CTLA-4 dual-affinity responsive target molecule
taxane
Prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT05440786
Advanced
Phase 2
Active not recruiting
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma
CDK4/6 inhibitor
alkylating agent
topoisomerase inhibitor
Ewing sarcoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05382286
Advanced
Phase 3
Active not recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (
ASCENT-04
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
2065 - St Leonards - GenesisCare North Shore Private Hospital
2217 - Kogarah - St George Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05359861
Advanced
Phase 2
Active not recruiting
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (
SRF388-201
)
anti-IL27 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05217446
Advanced
Phase 2
Active not recruiting
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER (
SEAMARK
)
BRAF V600 inhibitor
anti-EGFR monoclonal antibody
anti-PD-1 monoclonal antibody
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT02582697
Advanced
Phase 3
Unknown
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (34)
Active not recruiting (6)
Not yet recruiting (1)
Terminated (1)
Unknown (1)
Recruitment Country and State
VIC (37)
NSW (30)
QLD (19)
WA (19)
SA (14)
NZ (9)
TAS (3)
ACT (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (10)
Phase 2 (18)
Phase 3 (9)
Trial Type
Advanced (21)
Haem (19)
Curative (3)
Paediatric (1)
Cancer Therapy Class
PD-1/PD-L1
16%
BCL2
9%
PD-1
9%
BRAF
7%
RAF
7%
PD-L1
7%
CDK4
5%
oestrogen axis
5%
CD19
5%
IDH1
5%
IDH1 R132
5%
CD20
5%
CDK4 selective
2%
PI3K-delta
2%
PI3K
2%
PI3Kalpha
2%
mTOR
2%
mTORC1
2%
mTORC2
2%
B7H3
2%
CRAF
2%
pan-RAF
2%
CDK2
2%
ER
2%
MALT1
2%
TIGIT
2%
PRMT5
2%
JAK1
2%
JAK2
2%
HIF2a
2%
FACT complex
2%
GD2
2%
CD22
2%
proteasome
2%
EBV
2%
AXL
2%
FLT3
2%
IDH2
2%
cereblon
2%
CD7
2%
CTLA4
2%
polyamine transport
2%
CDK6
2%
Trop2
2%
IL27
2%
VEGF
2%
BRAF V600
2%
EGFR
2%
Facility
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (22)
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
2145 - Westmead - The Children's Hospital at Westmead (10)
3052 - Parkville - Royal Children's Hospital Melbourne (10)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (10)
3168 - Clayton - Monash Medical Centre (10)
2031 - Randwick - Sydney Children's Hospital (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
4101 - South Brisbane - Queensland Children's Hospital (8)
6009 - Perth - Perth Children's Hospital (8)
2139 - Concord - Concord Repatriation General Hospital (7)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (7)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (7)
6150 - Murdoch - Fiona Stanley Hospital (7)
2305 - New Lambton Heights - John Hunter Children's Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
5042 - Bedford Park - Flinders Medical Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
3004 - Melbourne, Southbank - Alfred Health (4)
NZ.1023 - Grafton - Starship Children's Hospital (4)
2031 - Randwick - Prince of Wales Hospital (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2485 - Tweed Heads - The Tweed Hospital (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (3)
3168 - Clayton - Monash Children's Hospital (2)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
6000 - Perth - Royal Perth Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2025 - Papatoetoe - Middlemore Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
4032 - Chermside - The Prince Charles Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3066 - Epping - Northern Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2217 - Kogarah - St George Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Leukaemia
Lymphoid leukaemia
Lymphoma
Neurological cancer
Acute lymphoblastic leukaemia
Myeloproliferative neoplasm
Central nervous system cancer
Sarcoma
Gastrointestinal cancer
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
Upper gastrointestinal cancer
Acute myeloid leukaemia
Myeloid leukaemia
Breast cancer
Gynaecological cancer
B-cell malignancy
Mature B-cell malignancy
Endometrial cancer
Chronic lymphocytic leukaemia
Glioma
Malignant glioma
Endocrine gland cancer
Bone cancer
Carcinoma
Ovarian cancer
B-cell lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Melanoma
Thyroid cancer
Mixed phenotype acute leukaemia
Soft tissue sarcoma
Ewing family of tumours
Gastric cancer
Gastroesophageal cancer
Lung cancer
Non-small cell lung cancer
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Thoracic cancer
Multiple myeloma
Plasma cell disorder
H3K27M-mutant glioma
High-grade glioma
Hepatobiliary cancer
Hepatocellular carcinoma
Urogenital cancer
Colorectal cancer
Lower gastrointestinal cancer
B-cell acute lymphoblastic leukaemia/lymphoma
Histiocytic and dendritic cell neoplasm
Histiocytic neoplasm
Langerhans Cell Histiocytosis
Low-grade glioma
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Atypical teratoid rhabdoid tumour
Central nervous system primitive neuroectodermal tumour
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
Myelofibrosis
Adrenal cancer
Gastro-entero-pancreatic neuroendocrine tumour
Gastrointestinal stromal tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Diffuse intrinsic pontine glioma
Osteosarcoma
Wilms tumour
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Chronic leukaemia
Chronic myelogenous leukaemia
T-cell acute lymphoblastic leukaemia/lymphoma
Male genital cancers
Prostate cancer
Cervical cancer
Differentiated thyroid carcinoma
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Mesothelioma
Oesophageal cancer
Papillary thyroid cancer
Pleural mesothelioma
Viral-related cancer
Ewing sarcoma
Primitive neuroectodermal tumour
Breast adenocarcinoma
Triple-negative breast cancer
Germ cell tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy